Historie von Umsatz, Gewinn und Cashflow aus den offiziellen Geschäftsberichten.
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain.
Interaktive Charts und vollständige Abschlüsse ansehen → Bewertungsmodell (DCF) →
| Gewinn- und Verlustrechnung | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gesamtumsatz | $12.6B | $12.1B | $11.0B | $9.9B | $8.9B | $7.6B | $6.2B | $4.2B | $3.0B | $2.5B | $1.7B | $1.0B | $580M | $1.2B | $1.5B | $1.4B | $143M | $102M | $176M | $199M | $216M |
| Bruttoergebnis | $10.9B | $10.3B | $9.5B | $8.6B | $7.8B | $6.7B | $5.5B | $3.6B | $2.6B | $2.2B | $1.5B | $907M | $519M | $1.1B | $1.2B | $1.3B | $131M | $88M | $160M | $185M | $204M |
| Bruttomarge % | 86.0% | 85.0% | 86.1% | 87.2% | 87.9% | 88.1% | 88.1% | 86.8% | 86.6% | 88.9% | 87.6% | 87.8% | 89.5% | 89.2% | 81.7% | 94.3% | 91.1% | 86.1% | 91.1% | 93.0% | 94.4% |
| Betriebsergebnis (EBIT) | $4.9B | $4.8B | ($233M) | $3.8B | $4.3B | $2.8B | $2.9B | $1.2B | $635M | $123M | $10M | ($469M) | ($692M) | ($903M) | $2M | $114M | ($696M) | ($613M) | ($463M) | ($420M) | ($229M) |
| Operative Marge % | 38.6% | 39.4% | -2.1% | 38.8% | 48.2% | 36.7% | 46.0% | 28.8% | 20.8% | 5.0% | 0.6% | -45.4% | -119.3% | -74.5% | 0.1% | 8.1% | -485.5% | -601.1% | -263.6% | -210.9% | -105.9% |
| Jahresüberschuss | $4.4B | $4.0B | ($536M) | $3.6B | $3.3B | $2.3B | $2.7B | $1.2B | $2.1B | $263M | ($112M) | ($558M) | ($739M) | ($445M) | ($107M) | $30M | ($755M) | ($642M) | ($460M) | ($391M) | ($207M) |
| Nettomarge % | 34.9% | 32.7% | -4.9% | 36.7% | 37.2% | 30.9% | 43.7% | 28.3% | 68.8% | 10.6% | -6.6% | -54.1% | -127.2% | -36.7% | -7.0% | 2.1% | -526.3% | -628.7% | -262.0% | -196.6% | -95.6% |
| EBITDA | $5.4B | $4.9B | $486M | $4.6B | $4.4B | $2.9B | $3.3B | $1.6B | $707M | $103M | $75M | ($411M) | ($599M) | ($555M) | $42M | $134M | ($705M) | ($599M) | ($426M) | ($385M) | ($200M) |
| Ergebnis je Aktie (EPS) | $17.18 | $15.32 | $-2.08 | $13.89 | $12.82 | $9.01 | $10.30 | $4.51 | $8.09 | $1.04 | $-0.46 | $-2.31 | $-3.14 | $-1.98 | $-0.50 | $0.14 | $-3.77 | $-3.70 | $-3.27 | $-3.03 | $-1.83 |
| Ausstehende Aktien (Mio.) | 256M | 258M | 258M | 260M | 259M | 260M | 263M | 261M | 259M | 253M | 245M | 241M | 235M | 225M | 212M | 209M | 200M | 173M | 141M | 129M | 113M |
Quelle: veröffentlichte Unternehmensberichte (SEC). Bitte prüfen Sie die Zahlen vor Verwendung auf SEC EDGAR.
Bilanzen, Cashflow-Rechnungen, Quartalsdaten und alle Kennzahlen finden Sie im interaktiven Viewer für VRTX. /companies/us/VRTX
Die Informationen auf dieser Website dienen ausschließlich Bildungs- und Informationszwecken und stellen keine Anlageberatung dar. Es werden keine Kursziele und keine Anlageurteile veröffentlicht.
About TickerBase · Data methodology & sources · Privacy · Terms